Kornimate/medical-research-clean huggingface dataset:
vitros immunodiagnostic products hs troponin i

Conditions: Acute Coronary Syndrome (ACS); Myocardial Infarction

Summary: the purpose of this clinical study is to collect data to substantiate the use of the vitros hs troponin i test as an aid in the diagnosis of myocardial infarction (mi). the test is further indicated for risk stratification of mortality, myocardial infarction or coronary revascularization in patients with acute coronary syndrome.

a prospective clinical sample collection and cardiac troponin i testing will be conducted in individuals presenting to the emergency department (ed) with signs and/or symptoms suggestive of acute coronary syndrome (acs) at geographically dispersed sites in the us. individuals who meet the inclusion/exclusion criteria, including having signed an informed consent form will be included in the study. clinical and laboratory data will be collected to demonstrate product performance compared to an adjudicated clinical diagnosis. sample collection and testing of clinical samples with the vitros hs troponin i test will be performed under two separate protocols.

Eligibility criteria:
inclusion criteria: 1. subject must be ≥22 years of age at the time of consent. 2. subject presenting with symptoms suggestive of acute coronary syndrome including chest pain, or chest pain equivalent. 3. must have an electrocardiogram (ecg) ordered as part of the subject's standard of care. 4. subject willing and able to provide informed consent. exclusion criteria: 1. subject is unable to comply with the study requirements. 2. any samples which were not obtained under irb approved protocol.

Keywords: troponin
the rehabilitation of atrophic jaws using short implants with different surface characteristics

Conditions: Peri-Implantation Loss; Periodontal Bone Loss; Periimplantitis; Gingival Inflammation; Implant Complication; Osseointegration Failure of Dental Implant

Summary: the aim of the research is to evaluate the clinical outcome of short dental implants, characterized by a new macro-structural design and inserted in the upper or lower jaw in patients with reduced bone volume. the clinical outcomes will be compared for different surface treatments of implant neck and those of prosthetic components.


Eligibility criteria:
inclusion criteria: * healthy patients, with edentulous maxillary or mandibular ridge, requiring rehabilitation with two adjacent implants; * at least 6 month after extraction; exclusion criteria: * post-extractive implants; * sites requiring bone regeneration or maxillary sinus lift; * general health problems that contraindicate implant treatment.

Keywords: short implants surface treatment
effect of ric on 2,3-bpg in erythrocyte (ric-bpg)

Conditions: 2,3-Bisphosphoglycerate

Summary: under hypoxia or high-altitude hypoxia ,it has been found that 2,3-bisphosphoglycerate(2,3-bpg) in erythrocyte increased and facilitated oxygen release to tissues.remote ischemic conditioning(ric) can also cause hypoxic conditions in local limbs.thus,we hypothesize that whether ric could also increase 2,3-bpg in erythrocyte.

ric is induced by short-term insulting blood-flow of nonvital distant organs intermittently and has been proved to be effective in ischemic stroke and myocardial infarction(mi).the possible mechanisms of ric protection is complicated.ric leads to local ischemia and hypoxia and has been demonstrated to play a role in vital organs through hypoxia inducible factors(hif) against stroke and mi.besides hif, hypoxia or high-altitude hypoxia could also change glycolytic process in erythrocyte through adenosine or sphingosine-1-phosphate(s1p).accompanying with alternating glucolysis, 2,3-diphosphoglycerate(2,3-bpg) in erythrocyte increases and it also facilitating oxygen release to tissues.thus,we hypothesize that whether ric could also increase 2,3-bpg in erythrocyte.there are 8 arms in this trial: all arms are ric treatment. the level of 2,3-bpg in erythrocyte will be assessed by elisa before and after the treatment.

Eligibility criteria:
inclusion criteria: 1. age:18-65 years old 2. healthy adults exclusion criteria: 1. individuals with various chronic diseases. 2. individuals with various acute diseases. 3. individuals who take any medicines 4. individuals who have taken health supplements for more than 2 weeks. 5. individuals with bmi\<18.5 or bmi≥24

Keywords: remote ischemic conditioning 2,3-bisphosphoglycerate erythrocyte oxygen healthy subjects
mdt-2113 drug-eluting balloon vs. standard pta for the treatment of atherosclerotic lesions in the superficial femoral artery and/or proximal popliteal artery

Conditions: Femoral Artery Stenosis; Popliteal Artery Stenosis; Femoral Artery Occlusion; Popliteal Artery Occlusion

Summary: the purpose of this trial is to assess the safety and efficacy of mdt-2113 for the interventional treatment of de novo and non-stented restenotic lesions in the superficial femoral artery (sfa) and the proximal popliteal artery (ppa) as compared to treatment with standard percutaneous transluminal angioplasty (pta).


Eligibility criteria:
inclusion criteria: * age: ≥ 20 years and ≤ 85 years * documented ischemia with rutherford classification 2, 3, or 4 * able to walk without assistive devices * target lesion is in the sfa and/or ppa above the knee * target lesion consists of a single de novo or non-stented restenotic lesion (or tandem lesions) or is a combination lesion that meets the following criteria: 1. ≥ 70% and \< 100% occluded with total lesion length ≥ 40 mm and ≤ 200 mm 2. 100% occluded with total lesion length ≤100 mm 3. combination lesions must have total lesion length ≥40 mm and ≤200 mm with an occluded segment that is ≤ 100 mm in length (by visual estimates) * reference vessel diameter ≥ 4 mm and ≤7 mm (by visual estimate) * angiographic evidence of adequate distal run-off through the foot exclusion criteria: * stroke or stemi within the 3 months prior to enrollment * either local or systemic thrombolytic therapy within the 48 hours prior to the index procedure * inability to tolerate oral anticoagulation therapy (blood thinners such as warfarin) while on concomitant dual antiplatelet therapy (dapt) * known allergies or sensitivities to heparin, aspirin (asa), other anticoagulant/antiplatelet therapies or to paclitaxel, or an allergy to contrast media that cannot be adequately pre-treated prior to the index procedure * chronic renal insufficiency * subject is enrolled in another investigational device, drug, or biologic study * any major surgical procedure or intervention performed within the 30-day period prior to or post index procedure * contralateral sfa/ppa disease requiring treatment in the same setting as index procedure * failure to successfully cross the target lesion * angiographic evidence of severe calcification * target lesion known in advance of enrollment to require treatment with alternative therapy such as stenting, laser, atherectomy, cryoplasty, brachytherapy, re-entry devices, cutting balloons, scoring balloons; use of embolic protection devices is also prohibited

Keywords: drug-eluting angioplasty balloon drug coated angioplasty balloon peripheral artery disease experimental percutaneous transluminal angioplasty (pta)
investigating the structured use of ultrasound scanning for fetal growth

Conditions: Stillbirth; Fetal Death; Fetal Growth Retardation; Small for Gestational Age; Fetal Growth Restriction; Perinatal Death; Intrauterine Growth Restriction

Summary: fetal growth restriction during pregnancy represents one of the biggest risk factors for stillbirth (gardosi et al, 2013), with 'about one in three term, normally formed antepartum stillbirths are related to abnormalities of fetal growth' (mbrrace, 2015). therefore, antenatal detection of growth restricted babies is vital in order to be able to monitor and decide the appropriate delivery timing. however, antenatal detection of sga babies has been poor, varying greatly across trusts in england in those that calculate their rates (nhs england, 2016). most trusts do not calculate their detection rates and rates are therefore unknown. it is estimated that routine nhs care detects only 1 in 4 growth restricted babies (smith, 2015). oxford university hospitals nhs foundation trust, in partnership with the oxford academic health science network (ahsn) has introduced a clinical care pathway (the oxford growth restriction pathway (oxgrip)) designed to increase the rates of detection of these at risk babies. the pathway is intended to increase the identification of babies who are at risk of stillbirth, in order to try to prevent this outcome, whilst making best usage of resources, and restricting inequitable practice and unnecessary obstetric intervention. it has been developed with reference to a body of research, however, the individual parts of care provided have not been put together in a pathway in this manner before. therefore it is important to examine whether the pathway meets its goals of improving outcomes for babies in a 'real world' setting. the principles of the pathway are 1. a universal routine scan at 36 weeks gestation. 2. additional growth scans at 28 and 32 weeks gestation based on a simplified assessment of risk factors and universal uterine artery doppler at 20 weeks gestation. 3. assessment of further parameters other than estimated fetal weight associated with adverse perinatal outcome (eg growth velocity, umbilical artery doppler and cpr). the clinical data routinely collected as a result of the introduction of the pathway offers a valuable and unique resource in identifying and analysing in the effects of the pathway on its intended outcomes and also in investigating and analysing other maternal, fetal and neonatal complications and outcomes, establishing normal / reference ranges for ultrasound values.

there is no requirement for patient participation in this study. all data collected and analysed is routinely collected clinical data.

Eligibility criteria:
inclusion criteria: • all pregnant women receiving antenatal care at the oxford university hospitals nhs foundation trust (ouhft) from january 2013 to 31st december 2019 with no exclusion criteria exclusion criteria: * women who have opted out of research related to pregnancy in this pregnancy whilst receiving care by the ouhft. * if intrapartum care takes place outside of the ouhft.
intergenerational transmission & igd

Conditions: Internet Gaming Disorder

Summary: this study aims to test the longitudinal association between parental igd and adolescent igd, after controlling for covariates at personal, interpersonal and familial levels and the mediation effects of parenting on the intergenerational transmission. this study is a two-year 3-wave longitudinal study. students and parents will complete questionnaires at time1, time2, and time3.

introduction adolescent internet gaming disorder (igd) causes severe physical, psychological, and social harms. family and parents play critical roles in adolescent igd. based on the socially-based intergenerational transmission theories, parental igd may increase the risk of adolescent igd directly and indirectly. objectives the primary objective is to test the longitudinal association between parental igd and adolescent igd, after controlling for covariates at personal, interpersonal and familial levels subjects and methods this study is a two-year 3-wave longitudinal study. adolescents will be recruited from secondary schools using stratified random sampling method. one parent of each adolescent will be invited. students will finish a set of validated psychological scales in class-room settings, while parents will finish their questionnaires through telephone interviews at time1, time2, and time3. outcomes and measures the primary outcome is adolescent igd symptoms based on dsm-5 igd symptoms checklist. the secondary outcomes include time spent on internet-related activities including gaming and gaming attitudes of adolescents. data analysis univariate and multivariate linear/logistic regression analyses will be conducted to test the associations between parental factors (including parental igd, parental modeling, and parenting practices) and adolescent igd. implications this study will clarify the level of adolescent igd in hong kong to inform policy and planning. it delineates mechanisms concerning intergenerational transmission of adolescent igd, and shed light on the development of timely and innovative prevention programs based on a family approach and evidence-informed parental training.

Eligibility criteria:
inclusion criteria (adolescent sample): * secondary 1-3 students (grade 7-9) * willingness to finish the study * chinese speaking * living with parent(s) inclusion criteria (parent sample): * father or mother of participating child * living with the participating child * willingness to finish the study * chinese speaking exclusion criteria (adolescent sample): * receiving treatment for mental disorders * intellectually disabled exclusion criteria (parent sample): * lack of competence in the chinese language * receiving treatment for mental disorders
can subthalamic stimulation using directional electrodes improve postoperative management in parkinson's disease

Conditions: Parkinson's Disease; Deep Brain Stimulation

Summary: the primary objective of the study is to determine if subthalamic nucleus (stn) deep brain stimulation (dbs) using the vercise directional leads improves neuropsychiatric state and neuropsychiatric fluctuations 12 months after surgery in a large consecutive series of stn-dbs parkinson's disease (pd) patients.

this project of further use of health-related data with consent by the participants is a prospective, international project to evaluate the improvement of neuropsychiatric symptoms and the quality of life 12 months after surgery in a large consecutive series of stn-dbs pd patients using novel implantable neurostimulator systems (boston scientific). the project will investigate if a fine tuning of the stn-dbs settings could alleviate neuropsychiatric fluctuations, apathy as well as dbs-induced dysarthria and global motor state. the tuning is performed in agreement with the instruction for use of all devices used. further objectives are validation of new tools that are presently entering clinical routine in optimizing postoperative management like individual current sources, steering, imaging of volume of tissue activated, and beta-oscillations. the data originates from patients suffering from levodopa-responsive pd which are not adequately controlled by dopaminergic medication and therefore receive stn-dbs as a routine standard of care with routinely collected data. in total 110 patients who are candidates for stn-dbs will be enrolled in four participating sites in switzerland and the eu.

Eligibility criteria:
inclusion criteria: for all subjects: * informed consent as documented by signature * diagnosis of pd based on the mds clinical diagnostic criteria for parkinson's disease * fulfilling criteria for stn-dbs: * the presence of disabling motor complications of dopaminergic treatment * the absence of surgical contraindications * planned bilateral stn-dbs using steering electrodes in the next 3 months (routine standard of care) exclusion criteria: * presence of dementia as indicated by a score ≤ 25 on the montreal cognitive assessment (moca) * depression with acute suicidal ideation * presence of major ongoing psychiatric illness * non-compensated systemic disease (i.e., diabetes, hypertension) * inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant * participation in interventional trial within the 30 days preceding and during the present study * previous enrolment into the current study * enrolment of any study site personnel, their family members, employees or other dependent persons

Keywords: apathy dysarthria neuropsychiatric symptoms steering non-motor symptoms motor state
effects of oxycodone combined with pregabalin on chronic postsurgical pain in spinal surgery

Conditions: Chronic Post Operative Pain; Oxycodone; Pregabalin; Postoperative Complications

Summary: chronic postoperative pain is one of the common perioperative complications, which seriously affects the prognosis of patients. currently, no specific perioperative pain management strategy has been found to be effective in preventing and treating chronic postoperative pain in patients undergoing spinal surgery. at present, oxycodone has been widely recognized in different surgical populations for the control of acute postoperative pain, but its contribution to chronic postoperative pain remains unknown. meanwhile, whether pregabalin can reduce the occurrence of chronic postoperative pain remains controversial, and whether the combination of the two drugs can control the occurrence of chronic postoperative pain in a more comprehensive way remains unknown. therefore, we intend to conduct this randomized-controlled, factorial design study to determine the efficacy and safety of oxycodone combined with pregabalin in the treatment of chronic postoperative pain in patients undergoing spinal surgery.


Eligibility criteria:
inclusion criteria: * patient undergoing elective spinal surgery * ages equal to or more than 18 years old * asa i-iii * signed informed consent exclusion criteria: * previous allergic history to gabapentinoids or oxycodone; * patients with aphasia or inability to cooperate with scales assessments; * patients with a diagnosed history of psychiatric disorder; * known severe insufficiency of vitals(such as heart failure/renal dysfunction/hepatic failure); * patients treated with gabapentin/pregabalin in the last three months; * history of drug abuse; * body mass index more than 35 kg/㎡; * pregnant or breastfeeding woman.
observation of intraosseous vascular access in the emergency department

Conditions: Patients Requiring Urgent Vascular Access

Summary: the purpose of this study is to evaluate the use of powered intraosseous vascular access (ez-io by vidacare) in the emergency department for patients requiring urgent vascular access. data collected will be compared to historical data on central venous catheter use in the emergency department. the primary hypothesis is that powered intraosseous vascular access will decrease the amount of time needed to obtain vascular access.


Eligibility criteria:
inclusion criteria: * patients requiring vascular access who would otherwise receive a central venous catheter due to lack of other options. exclusion criteria: * fracture in target bone, or significant trauma to the site * excessive tissue and/or absence of adequate anatomical landmarks in target bone * infection in target area * io insertion in past 24 hours, prosthetic limb or joint or other significant orthopedic procedure in target bone
system-igf-1 pathway and alzheimer's disease

Conditions: Alzheimer's Disease; Mild Cognitive Impairment; Cognitive Function 1, Social; Control With Normal Activities of Daily Living

Summary: the aim is to assess the relationship between levels of igf-i system components and cognitive status in patients with alzheimer's disease (ad), in elderly subjects with normal cognitive function, and in patients with mild cognitive impairment (mci).

ad is the most common cause of dementia. during aging, decline of biological brain functions due to a number of genetic and environmental factors facilitates the onset of ad. mci includes prodromal ad. the identification of the risk factors for ad must be a priority in order to define the best therapeutic approach. recent data support the notion that igf-i pathway accounts for neuronal protection, with a dual effect, on both brain aβ peptide and tau protein. this large, multicenter, prospective, observational, cross-sectional population-based study in 3 parallel groups (200 participants per group) is aimed to assess differences between igf-i and igfbp3 circulating levels and polymorphisms in ad patients and control elderly subjects, and in mci patients.

Eligibility criteria:
inclusion criteria: caucasian patients after a comprehensive geriatric assessment and giving informed written consent. - in each arm : 1. elderly subjects with normal cognitive function, 2. patients with dementia of ad type (dsm-iv and nincds-adrda criteria), 3. patients with mci (european consortium on alzheimer's disease, eadc). exclusion criteria: non ad dementia major depression use of anticholinesterase agent all diseases or major sensory deficits or any condition that might interfere with cognitive assessment and study objectives

Keywords: insulin-like growth factor insulin-like growth factor binding protein 3 insulin-like growth factor-i system component levels insulin-like growth factor-i polymorphism alzheimer's disease mild cognitive impairment normal cognitive function observational cross sectional study
text messaging follow-up from ed

Conditions: Text Messaging

Summary: ensuring follow-up for patients after discharge from the emergency department (ed) has long been a concern for ed care providers. the current technology of text messaging may be able to assist us in improving follow-up rates. in addition, having a quick and easy communication tool to be in touch with providers may improve overall patient satisfaction. this study is designed to evaluate the usage of text messaging to improve follow-up appointment compliance from the emergency department. in this study, a prospective randomized controlled trial (rct) will be performed (involving patients scheduled by emergency department nurse navigators to follow up with family medicine) in which patients will be randomized to a texting appointment reminder versus standard-of-care (no texting reminder) group. texted patients will receive reminders 3 days and 1 day prior to their follow-up appointment. in addition, the patients will have the ability to text back-and-forth with the nurse navigators in order to ask questions/request clarification if needed. chart review will be performed of both groups to evaluate the number of follow-up appointments that patients attended versus rescheduled versus did not attend/reschedule. these values will then be compared to the retrospective chart review previously performed to evaluate for non-inferiority of text messaging as a means of improving patient attendance at follow-up appointments.


Eligibility criteria:
inclusion criteria: 1. at least 18 years old 2. able to read, write and communicate in english - english as the primary language 3. has a phone with capabilities for text messaging 4. identifies oneself as someone who is comfortable with text messaging. 5. to follow-up with family medicine as outpatient (scheduled through emergency department nurse navigators). 6. evaluated in the university of iowa hospitals and clinics emergency department exclusion criteria: 1. absence of one or more inclusion criteria 2. not able to provide informed consent or participate due to limited decision-making ability. 3. prisoner 4. previously has followed with the university of iowa hospitals and clinics family medicine (i.e., would not be a "new" patient establishing care).